GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Other Financing

Gensight Biologics (XPAR:SIGHT) Other Financing : €-0.28 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Other Financing?

Gensight Biologics's Other Financing for the six months ended in Dec. 2024 was €-0.22 Mil.

Gensight Biologics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.28 Mil.

Gensight Biologics Other Financing Historical Data

The historical data trend for Gensight Biologics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Other Financing Chart

Gensight Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.71 27.26 -1.87 -0.37 -0.28

Gensight Biologics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.46 -0.27 -0.20 -0.06 -0.22

Gensight Biologics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Other Financing Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Other Financing
Comparable Companies
XPAR:ALGAE XPAR:ABNX XPAR:ALGEN XPAR:POXEL XPAR:ALDVI XPAR:AELIS XPAR:ALCOX XPAR:ALVAL XPAR:ALNFL XPAR:ALPAT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
0RIM:UK
Address
74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Website
https://www.gensight-biologics.com
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology, where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics Headlines

No Headlines